Axsome Therapeutics, Inc. AXSM
We take great care to ensure that the data presented and summarized in this overview for Axsome Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXSM
View all-
Vanguard Group Inc Valley Forge, PA3.88MShares$417 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$355 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.92MShares$314 Million5.58% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$182 Million8.66% of portfolio
-
Macquarie Group LTD Australia, C3976KShares$105 Million0.14% of portfolio
-
Geode Capital Management, LLC Boston, MA935KShares$100 Million0.01% of portfolio
-
State Street Corp Boston, MA906KShares$97.4 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA857KShares$92.1 Million0.02% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA815KShares$87.6 Million32.39% of portfolio
-
Eventide Asset Management, LLC Boston, MA745KShares$80.1 Million1.84% of portfolio
Latest Institutional Activity in AXSM
Top Purchases
Top Sells
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Transactions at AXSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 23
2025
|
Hunter R. Murdock General Counsel |
SELL
Open market or private sale
|
Direct |
6,014
-100.0%
|
$601,400
$100.12 P/Share
|
|
Jun 23
2025
|
Hunter R. Murdock General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,014
+50.0%
|
$174,406
$29.91 P/Share
|
|
Jun 20
2025
|
Hunter R. Murdock General Counsel |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$765,000
$102.47 P/Share
|
|
Jun 20
2025
|
Hunter R. Murdock General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$217,500
$29.91 P/Share
|
|
Jun 18
2025
|
Hunter R. Murdock General Counsel |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$750,000
$100.9 P/Share
|
|
Jun 18
2025
|
Hunter R. Murdock General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$217,500
$29.91 P/Share
|
|
Jun 17
2025
|
Hunter R. Murdock General Counsel |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$750,000
$100.26 P/Share
|
|
Jun 17
2025
|
Hunter R. Murdock General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$217,500
$29.91 P/Share
|
|
Jun 16
2025
|
Hunter R. Murdock General Counsel |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$765,000
$102.42 P/Share
|
|
Jun 16
2025
|
Hunter R. Murdock General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$217,500
$29.91 P/Share
|
|
Jun 09
2025
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-81.21%
|
$2,750,000
$110.44 P/Share
|
|
Jun 09
2025
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+44.82%
|
$200,000
$8.02 P/Share
|
|
May 28
2025
|
Mark Coleman |
SELL
Open market or private sale
|
Direct |
3,750
-7.44%
|
$386,250
$103.43 P/Share
|
|
May 28
2025
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-77.57%
|
$2,060,000
$103.45 P/Share
|
|
May 28
2025
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+43.68%
|
$120,000
$6.47 P/Share
|
|
May 27
2025
|
Mark Coleman |
SELL
Open market or private sale
|
Direct |
3,750
-6.93%
|
$393,750
$105.47 P/Share
|
|
May 27
2025
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,673
-78.14%
|
$2,149,992
$104.66 P/Share
|
|
May 27
2025
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,673
+43.86%
|
$124,038
$6.47 P/Share
|
|
May 20
2025
|
Mark Coleman |
SELL
Open market or private sale
|
Direct |
3,000
-5.25%
|
$321,000
$107.49 P/Share
|
|
Feb 14
2025
|
Nick Pizzie Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.64%
|
$393,000
$131.07 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 218K shares |
|---|
| Open market or private sale | 186K shares |
|---|